ARAF and cancer: Inactivating mutations of PKs have been identified only in a small number of human cancers, indicating that modifications in kinase activity by phosphorylation are among the main causes of disease progression, and that phospho-proteomic screens could be useful to monitor cancer development and to identify new potential therapeutic targets.